Department of Endocrinology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, China.
Anhui University of Traditional Chinese Medicine, Hefei, China.
Ann Med. 2023;55(2):2291185. doi: 10.1080/07853890.2023.2291185. Epub 2023 Dec 26.
To observe the effect of Danzhi Jiangtang capsule (DJC) on the clinical indexes and vascular endothelial function indexes in patients with impaired glucose tolerance (IGT).
A total of 106 patients were enrolled and randomly assigned to the treatment group and control group following a four-week washout period. The patients in the control group received a general lifestyle intervention, while those in the treatment group received DJC (2.0 g 3× a day) in conjunction with the intervention given to the control group patients. The physiological and biochemical levels, vascular endothelial function indices, and traditional Chinese medicine (TCM) syndrome ratings of the patients in the two groups were compared after 12 weeks of therapy.
In the control group, the diastolic blood pressure (DBP) was significantly improved compared with those before treatment (83.31 ± 6.47 vs. 79.21 ± 6.17, < .01) (CI: 1.45, 6.73; Cohen's : 10.51), as was the case with the nitric oxide (NO) levels and TCM syndrome points (35.71 ± 4.58 vs. 43.96 ± 5.17, 9.57 ± 2.63 vs. 5.38 ± 1.79, < .001) (CI: -10.28, -6.24; 3.12, 5.18; Cohen's : 0.90). In the treatment group, the levels of fasting blood glucose, endothelin and vascular endothelial growth factor were significantly improved compared with control group (4.92 ± 0.21 vs. 5.59 ± 0.31, 59.37 ± 13.25 vs. 72.13 ± 12.37, 19.25 ± 2.80 vs. 26.76 ± 1.88, < .001) (CI: 0.55, 0.78; 7.40, 18.13; 6.52, 8.50; Cohen's : 4.94, 0.41, 1.32), as was the case with 2-h post-load plasma glucose and total cholesterol (TC) (8.33 ± 0.62 vs. 8.89 ± 1.55, 4.61 ± 1.05 vs. 5.22 ± 1.12, < .05) (CI: 0.07, 1.07; 0.15, 1.06; Cohen's : 0.40, 0.51).
Treatment with DJC could significantly improve the physiological and biochemical indicators, vascular endothelial function, and TCM syndrome points of IGT patients, indicating that DJC could be a potential drug to treat patients with IGT of Qi-Yin deficiency type.
观察丹蛭降糖胶囊对糖调节受损（IGT）患者临床指标及血管内皮功能指标的影响。
将 106 例患者采用洗脱期（4 周）后，随机分为治疗组和对照组。对照组给予一般生活方式干预，治疗组在对照组治疗的基础上加用丹蛭降糖胶囊（2.0 g，3 次/d）治疗。治疗 12 周后，比较两组患者的生理生化指标、血管内皮功能指标和中医证候评分。
对照组治疗后舒张压（DBP）[（83.31±6.47）mmHg 比（79.21±6.17）mmHg，<0.01]、一氧化氮（NO）水平[（35.71±4.58）μmol/L 比（43.96±5.17）μmol/L，9.57±2.63 比（5.38±1.79），<0.001]、中医证候积分[（9.57±2.63）分比（5.38±1.79）分]均较治疗前改善（差值分别为 1.45、-8.19、4.19，CI：1.45，6.73；9.57，5.18； Cohen's d：10.51、0.90）。治疗组治疗后空腹血糖、内皮素和血管内皮生长因子水平[（4.92±0.21）mmol/L 比（5.59±0.31）mmol/L、（59.37±13.25）pg/ml 比（72.13±12.37）pg/ml、（19.25±2.80）ng/L 比（26.76±1.88）ng/L]均较对照组改善（差值分别为-0.55、-12.76、-7.47，CI：-0.55，0.78；-7.40，18.13；-6.52，8.50； Cohen's d：4.94、0.41、1.32），餐后 2 h 血糖、总胆固醇[（8.33±0.62）mmol/L 比（8.89±1.55）mmol/L、（4.61±1.05）mmol/L 比（5.22±1.12）mmol/L]均较对照组改善（差值分别为-0.56、-0.61，CI：-0.07，1.07；-0.15，1.06； Cohen's d：0.40、0.51）。
丹蛭降糖胶囊可显著改善 IGT 患者的生理生化指标、血管内皮功能及中医证候积分，提示丹蛭降糖胶囊可能是治疗气阴两虚型 IGT 患者的潜在药物。
